ArticleBMC chemistry2026
A novel green QbD-optimized RP-HPLC bioanalytical method for the simultaneous determination of doxorubicin and rifampicin in human plasma.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin hydrochloride (DOX) remains a cornerstone in the treatment of numerous malignancies. Recent research has focused on improving the efficacy of chemotherapeutic regimens through synergistic combinations. Rifampicin (RFP), in addition to its well-known antimicrobial properties, exhibits chemosensitizing potential, making it a promising adjuvant to DOX therapy. In this study, a robust and eco-friendly HPLC method was developed and optimized for the simultaneous determination of DOX and RFP. Chromatographic separation was achieved on a C18 column (150 × 4.6 mm, 5 μm particle size) at 25 °C, using an isocratic mobile phase composed of acetonitrile and phosphate buffer (0.02 M, pH 5.43) in a 34.85:65.15 (v/v) ratio, with a flow rate of 0.8 mL/min and UV detection at 254 nm. The method was systematically optimized using a Quality-by-Design (QbD) approach with a full factorial design to assess the influence of key variables on chromatographic performance. The optimized chromatographic separation was achieved within 7 min, with retention times (Rts) of 3.26 min of DOX and 6.62 min for RFP. Excellent linearity was obtained over the ranges of 1.0-40.0 µg/mL for DOX and 1.0-30.0 µg/mL for RFP, with high determination coefficients (r² ≥ 0.999) and lower detection limits of 0.44 µg/mL and 0.39 µg/mL and quantitation limits of 1.35 µg/mL and 1.18 µg/mL, respectively. Greenness evaluation using the Analytical Greenness (AGREE) and Analytical Green Star Area (AGSA) metrics confirmed the method's high environmental sustainability. When applied to spiked human plasma samples, recovery values ranged from 92.38% to 107.20% with low %RSD, demonstrating strong accuracy, precision, and bioanalytical applicability. Overall, the developed method represents the first simple, sensitive, and environmentally benign analytical approach for the simultaneous quantification of doxorubicin HCl and rifampicin in biological matrices, making it highly suitable for routine therapeutic drug monitoring (TDM) in clinical and pharmacokinetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.